Created at	Source	Raw Value	Validated value
Feb. 17, 2022, 5 p.m.	usa	Number of Participants Until First Non-detectable SARS-CoV-2 in Nasopharyngeal (NP) Swabs;Number of Participants With Adverse Events (AEs) Grade 3 or Higher or Leading to Discontinuation of Study Treatment;Time to Clearance of SARS-CoV-2 in Nasopharyngeal Swabs	Number of Participants Until First Non-detectable SARS-CoV-2 in Nasopharyngeal (NP) Swabs;Number of Participants With Adverse Events (AEs) Grade 3 or Higher or Leading to Discontinuation of Study Treatment;Time to Clearance of SARS-CoV-2 in Nasopharyngeal Swabs
Oct. 26, 2020, 11:31 p.m.	usa	Number of Participants with any Adverse Events (AEs) as Assessed by Kaplan Meier Approach;Virologic Efficacy	Number of Participants with any Adverse Events (AEs) as Assessed by Kaplan Meier Approach;Virologic Efficacy